Consort Medical has announced that it has created a single source supply chain for OINDPs by combining the services of device company Bespak with CDMO Aesica, which Consort acquired in September 2014. Together, the companies can supply API, formulation, and device development; pilot scale to commercial manufacturing; finished dose fill and finish; and secondary packaging.
According to Consort, both companies operate to FDA and MHRA standards, and Aesica can handle potent drugs up to SafeBridge category 3 and controlled substances up to schedule 2.
Aesica Pharmaceuticals Managing Director Ian Muir and Bespak Managing Director Keyvan Djamarani said, “Our highly innovative business model, which optimizes drug and device services in a single group, serves to streamline and accelerate our pharmaceutical partners’ route to market and, at the same time, to reduce the cost and complexity of drug and device development. We confidently believe that the demand from the market for a single source service offering from a single provider will increase.”
Read the Consort Medical press release.
